Compare American Express Co (AXP) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs DexCom, Inc. — how do they compare? American Express Co trades at $341.38 (market cap $230.15B), while DexCom, Inc. trades at $90.26 (market cap $33.79B). The key difference: American Express Co is far larger — about 6.8× DexCom, Inc.'s market cap, and American Express Co pays a 1.11% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| AXP | DXCM | |
|---|---|---|
Market Cap | $230.15B | $33.79B |
Sector | Financials | Health |
52-Week High | $384.82 | $89.53 |
52-Week Low | $292.27 | $54.84 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $341.25, up 0.7% on the day, with a bullish technical signal and strong support at $339. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.07% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Buy with a $369.42 price target. News highlights Amex Ventures' AI investments and premium cardmember perks.
Outlook is positive given earnings momentum and strategic AI bets, but risks include rising debt levels and competitive pressure. The stock offers growth potential with a reasonable P/E of 20.68, though investors should watch for economic sensitivity in consumer spending.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
